Antiviral Res 2005, 67: 155–62.CrossRefPubMed 25. Faith SA, Sweet TJ, Bailey E, Booth T, Docherty JJ: Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells. Antiviral Res 2006, 72: 242–251.CrossRefPubMed 26. Hirt B: Replicating molecules

of polyoma virus DNA. J Mol Biol 1969, 40: 141–144.CrossRefPubMed 27. Mosmann T: Rapid colorimetric assay for cellular grow and survival: application to LY294002 concentration proliferation and cytotoxixity assay. J Immunol Methods 1983, 65: 55–63.CrossRefPubMed 28. Delmas D, Lançon A, Colin D, Jannin B, Latruffe N: Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 2006, 7: 423–442.CrossRefPubMed 29. Saiko P, Pemberger M, Horvath Z, Savinc I, Grusch M, Handler N, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T: Novel resveratrol

analogs induce apoptosis and cause cell cycle CB-5083 manufacturer arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity. Oncol Rep 2008, 19: 1621–1626.PubMed 30. Juan ME, Wenzel U, Daniel H, Planas JM: Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J Agric Food Chem 2008, 56: 4813–4818.CrossRefPubMed 31. Singh M, Singh N: Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem Gamma-secretase inhibitor 2009, 325: 107–119.CrossRefPubMed 32. Lilley BN, Gilbert JM, Ploegh HL, Benjamin TL: Murine polyomavirus requires the endoplasmatic reticulum protein Derlin-2 to initiate infection. J Virol 2006, 80: 8739–4.CrossRefPubMed Competing interests Authors declare that no conflicting or competing interests, of any nature, exist between the Authors of this work and their Academic activity. Authors’ contributions All Authors equally contributed to the completion of this work.”
“Background Intracavitary brachytherapy (ICBT) with external radiotherapy (ERT) is

an essential component of cervical cancer management and has a high therapeutic index by delivering a high dose to the primary cervical lesion and lower doses to adjacent organs, resulting in increased local control and survival without increased in toxicity [1–4]. However the doses delivered to tumor and normal tissues from ICBT are difficult to quantify accurately in conventional Terminal deoxynucleotidyl transferase brachytherapy (BRT) planning. To ensure consistency in the reporting of ICBT applications in cervical cancer, the International Commission on Radiation Units and Measurement (ICRU) recommended a number of parameters for doses and volumes to be considered. These include points A and B, representing the doses in the parametria and the pelvic wall, and the rectal and bladder points representing the organs at risk (OARs), respectively [5]. Physicians have used these reference point doses to report treatment intensity and to estimate the maximal dose to normal tissues, which can predict late complications.